| P/E (FY) | — | Sales (TTM) | $2.0M |
| Earnings (TTM) | -$97.6M | ROE | — |
| Net Margin | −2003.58% | ROIC | — |
| Debt / Equity | 11.40 | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
Humacyte develops and manufactures off-the-shelf, implantable, bioengineered human tissues to treat diseases and conditions across multiple therapeutic areas. Using a proprietary technology platform, it engineers human acellular vessels designed for implantation without inducing a foreign body response or immune rejection. Its portfolio targets vascular repair, reconstruction, and replacement markets, including vascular trauma, arteriovenous access for hemodialysis, peripheral arterial disease, pediatric heart surgery, and coronary artery bypass grafting, as well as delivery of cellular therapy.
| Market Cap | $138.7M | Trading Days | 1228 |
| 52W High | 2.75 |
| 52W Low | 0.55 |
| % Off High | −77.33% |
| YTD | −35.01% | 1Y | −73.65% |
| 3Y | −80.96% | Since incept. (ann.) | −46.35% |
Product 68% · Product And Service Other 32%
| Ann. Volatility (1Y) | 114.59% | Ann. Volatility (3Y) | 108.24% |
| Sharpe (1Y) | −0.63 | Sharpe (3Y) | 0.05 |
| Max Drawdown (1Y) | −76.81% | Max Drawdown (3Y) | −93.92% |
| Beta (3Y, vs SPY) | 4.49 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| CRBU | Caribou Biosciences, Inc. | $145.8M | — |
| OTLK | Outlook Therapeutics, Inc. | $120.9M | — |
| TNYA | Tenaya Therapeutics, Inc. | $159.5M | — |
| IVVD | Invivyd, Inc. | $160.0M | — |
| ENGN | enGene Therapeutics Inc. | $119.9M | 0.8 |
| ABOS | Acumen Pharmaceuticals, Inc. | $164.7M | — |
| CRDL | Cardiol Therapeutics Inc. | $115.3M | — |
| ALEC | Alector, Inc. | $168.8M | — |
| VXRT | Vaxart, Inc. | $113.8M | 6.7 |
| DTIL | PRECISION BIOSCIENCES INC | $177.8M | — |
| BCDA | BioCardia, Inc. | $178.2M | — |
| LENZ | LENZ Therapeutics, Inc. | $179.3M | — |